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1. Introduction 
Blood is a vital component for the living being to be alive. The composition of blood is 
plasma and blood cells. It helps in transport of gaseous, metabolic products, hormones, 
nutrients and enzymes. It helps to regulate the body temperature and body fluid electrolyte. 
Blood transfusion becomes a vital part during blood loss, due to severe anemic condition 
and during major surgeries. Despite their critical use, blood transfusion becomes risky these 
days by the transmission of viruses. 
2. Basic information about viruses and blood transfusion 
The viruses are known for its replication and functional activities inside the cells. They 
usually need a system to be ‘alive’. Outside the cells or any living tissue, the viruses are 
dormant. Virus can be transmitted by various ways to human beings. The virus like 
hepatitis virus and its subtypes A, B, C, D, E and G, human immunodeficiency virus types 1 
and 2 (HIV-1/2), human T-cell lymphotropic virus types I and II (HTLV-I/II), 
cytomegalovirus (CMV), Epstein-Barr virus (EBV), TT virus (TTV), human herpes virus type 
6 (HHV-6), SEN virus (SEN-V), human parvovirus (HPV-B19) and West Nile Virus (WNV) 
has already been diagnosed and researched for its potential to cause disease via blood 
transfusion (Table 1). The viruses namely, Japanese encephalitis virus, WNV, Chikungunya 
virus, HIV, HHV, HTLV and rabies are even capable of entering into central nervous system 
through blood (Kristensson, 2011). However, some viruses are neither studied for their 
transmission through blood; because of little evidence to support their transmission and, 
even in some viruses the mode of transmission is not known. We would like to give more 
priority to Borna disease virus and Dengue virus, which has been less studied in terms of 
transmission and blood transfusion. 
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Virus Mode of transfusion Disease due to transmission 
HBV, 
HCV, 
HIV-1/-2, 
HTLV-I/-II 
Highly established Yes 
CMV, 
EBV, 
HAV, 
HPV-B19, 
HHV-6 
Established 
Only in immunocompromised 
state 
Dengue, 
WNV 
Rarely established Not conclusive 
HGV/GBV-C, 
TTV, 
SEN-V, 
HEV, 
HHV-8, 
BDV 
Not well established Not established 
Table 1. Recognized mode of viral transmission and disease in human. 
3. Borna disease virus 
Borna disease, a fatal meningo-encephalitis was originally described in horses in Germany. 
The disease was named after the epidemic outbreak of equine deaths in the town Borna in 
Saxony, Germany in 1885 (Rott and Becht, 1995). In 1929, an infectious agent was said to the 
cause for Borna disease and, in 1990 the infectious agent was identified as virus (Cubitt and 
de la Torre, 1994). The virus was then named after the disease, Borna disease virus (BDV). 
3.1 BDV genome 
BDV is said to be the only non-segmented, negative sense RNA virus replicated in the 
nucleus and classified as a new family Bornaviridae under Mononegavirales (Briese et al., 1994; 
de la Torre, 2002; De La Torre et al., 1996; Ludwig et al., 1988; Ludwig et al., 1993). BDV has 
six open reading frames (ORF), namely nucleoprotein (N), phosphoprotein (P), matrix (M), 
L-polymerase (L), glycoprotein (G) and X protein (Briese et al., 1994; de la Torre, 1994). The 
BDV mRNA includes monocistronic, polycistronic and spliced transcripts with overlapping 
ORFs (Kobayashi et al., 2003). The structural proteins are nucleoprotein, matrix and 
glycoprotein and the functional proteins are L-polymerase, phosphoprotein and X protein. 
The G protein helps in entry of BDV into the host cells. The G protein is expressed as two 
products, 84 and 43kDa. The 84kDa protein is involved in attachment of the viral particles to 
the cell receptor and its cleavage product 43kDa is involved in pH-dependent fusion after 
internalization of the virion by endocytosis (Gonzalez-Dunia et al., 1998). The M protein 
observed as tetramers and octamers, helps in viral attachment to cellular membrane, 
essential for viral assembly and budding (Kraus et al., 2005; Stoyloff et al., 1997). The M 
protein is also an integral component of ribonucleoprotein complex (RNP) and, prerequisite 
for viral persistence in the neurons (Chase et al., 2007). The structural information on M 
protein, suggest that they involve in RNP formation, nucleocapsid targeting and viral 
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maturation (Neumann et al., 2009). The L protein is involved in replication and P protein is 
involved in transcription of the BDV genome (Schneider, 2005). Further, the P protein 
interacts with other structural and functional proteins of BDV genome (Schwemmle et al., 
1998). The L protein is tightly regulated by N-P stoichiometric ratio (Schneider, 2005; 
Schneider et al., 2005; Walker et al., 2000; Walker and Lipkin, 2002). The X protein is 10kDA 
protein, interacts with P protein and, acts as a negative regulator of BDV polymerase and 
hinders viral replication (Poenisch et al., 2004; Poenisch et al., 2007; Schwardt et al., 2005). 
3.2 Behavioural effects of BDV infection in animals 
Behavioural alternations during viral infection are referred as ‘sickness behaviour’ that 
include alternation in body weight, taste preferences, temperature, food and water intake 
and sleep pattern (Kelley et al., 2003). The ‘sickness behaviour’ in BDV infected rats, shows 
body weight stunting and abnormal salt preferences (Hornig et al., 2001), high obese rate 
(Herden et al., 2000) and chronic emotional abnormalities (Pletnikov et al., 2002a; Pletnikov 
et al., 2002b, c).   
3.3 Prevalence of BDV infection in psychiatric illness 
The first isolation of BDV was from a patient with mood disorder (Bode et al., 1996). There 
have been totally six BDV isolates and the source of isolation was blood and brain tissues 
from patients with psychiatric illness. The six isolates of BDV are from blood samples of two 
bipolar disorder patients, one obsessive-compulsive disorder, one depression, one 
schizophrenic patient and one from brain tissue from a patient with schizophrenia in Japan 
(Bode and Ludwig, 2003). In this decade, many reports have been emphasizing BDV 
infection in psychiatric illness. The psychiatric illness includes depression, bipolar disorder, 
obsessive-compulsive disorder, severe mood disorder and non-psychotic bipolar disorder 
(Bode, 1995; Bode et al., 1997; Bode et al., 1996; Bode et al., 1992; Bode et al., 2001; Dietrich et 
al., 2000; Dietrich et al., 2005; Ohlmeier et al., 2007). The infection of BDV was analysed by 
western blot, ELISA, immunofluorescence assay, immunoprecipitation, circulating immune 
complexes (CIC) from the serum of the patients with psychiatric illness, affective disorder, 
schizophrenia and multiple sclerosis (Hornig et al., 2003). Apart from BDV antibodies, BDV 
RNA was found in peripheral blood cells of psychiatric patients (Miranda et al., 2006; 
Sauder et al., 1996). Bode et al., (2001) reported that BDV-CIC play a major role in detection 
of BDV activity in contrast to the state of illness. The high amount of CIC and plasma 
antigen correlates with the severity of depression. It was also found in the neurophysiologic 
studies that brain potential amplitude varies with BDV-CIC in obsessive-compulsive 
disorder (Dietrich et al., 2005).  
3.4 Neurotrophism or trophism for BDV infection 
Neurotrophism or trophism for BDV infection is not clearly understood. BDV was found to 
replicate in the neurons of limbic structures especially in the regions of hippocampus 
(Carbone et al., 1991a; Carbone et al., 1989). Hippocampus is rich in neurotrophic growth 
factors like nerve growth factor (NGF) (Nieto-Sampedro and Bovolenta, 1990) as well as in 
kinases (Olive and Hodge, 2000). 
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3.4.1 Nerve growth factor (NGF) as a neurotrophic factor 
Hippocampus is said to be the preferred site for replication of BDV as it is rich in growth 
factors (Ojika and Appel, 1984). NGF affects the replication cycle of other viruses and 
associated with latent HSV infection; the absence or removal of NGF is associated with 
recrudescence of productive HSV replication (Clements and Kennedy, 1989; Wilcox and 
Johnson, 1988; Wilcox et al., 1990). Carbone et al., (1993) suggested that NGF to be the 
neurotrophic factor influencing the replication of BDV. It was found that astrocytic cell lines 
were able to produce more BDV protein and RNA and suggested that astrocytic cells secrete 
a factor or factors that enhance the production of BDV protein and BDV RNA. It has also 
been found that NGF treatment was also produced the same as in astrocytic cell lines 
(Carbone et al., 1993). 
3.4.2 Protein Kinase C (PKC) as a trophic factor 
The P protein is involved in replication and also acts as a transcription factor. It has the 
nuclear localization signal that helps in transportation of P, L and X proteins into the 
nucleus (Schneider, 2005; Shoya et al., 1998; Walker et al., 2000; Walker and Lipkin, 2002). P 
protein is directly involved in glial cell dysfunction by reducing Brain Derived Growth 
Factor (BDNF) and serotonin receptor expression that results in neuropathological and 
neurophysiological abnormalities (Kamitani et al., 2003). The P protein is activated by 
phosphorylation. The kinases responsible for phosphorylation of P protein are Protein 
Kinase C (PKC)ε and Casein Kinase II. The major phosphorylation is through PKCε and the 
minor is from Casein Kinase II (Schwemmle et al., 1997). PKCε is present in higher 
concentrations in neuronal than in glial nuclei and are located inside the nucleus and at the 
nuclear envelope in brain cell nuclei (Rosenberger et al., 1995). It is found higher in the limbic 
structures (Olive and Hodge, 2000). BDV blocks neuronal presynaptic activity by inhibiting 
PKC signalling (Volmer et al., 2006), which was proved by P mutant phenotype where BDV is 
not able to interfere with neuronal signalling (Prat et al., 2009). The recent report indicate that 
PKC mediated signalling is necessary for viral spread (Schmid et al., 2010), which further 
proves that PKC is as tropic factor for BDV replication in hippocampal neurons.   
3.5 Molecular basis of human mental disorder in virus-induced neurobehavioral 
disorder 
Brain damage is usually observed in neurotrophic virus infection. The mechanism of virus 
induced neural damage occurs by direct and indirect pathways. The direct pathway 
involves viral replication in the nucleus leading to direct cell lysis or apoptosis. This was 
more commonly observed in infections with HSV, rabies virus, reovirus and alphavirus 
(Griffin and Hardwick, 1999). In case of BDV infection in rat models, the virus can cause 
neuronal cell dysfunctions in the absence of immune mediated cell destruction leading to 
neurological disorder (Tomonaga et al., 2002). The indirect pathway involves the 
modulation of host response to the viral infection. In BDV infection, the modulation occurs 
by the infiltrating immune cells such as CD4-positive, CD8-positive T-cells, macrophages 
and B cells. CD8-positive T cells represent the effector cell population exhibiting antigen 
specificity for the nucleoprotein (Stitz et al., 2002). Administration with anti-CD8+ results in 
reduction of neuronal degeneration and inhibits inflammation (Bilzer and Stitz, 1994). 
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Proinflammatory cytokines also play an important role in BDV infection, which alter the 
behaviour (Konsman et al., 2002). 
3.5.1 Role of proinflammatory cytokines 
Proinflammatory cytokines like IL-1ǂ, IL-1ǃ, IL-6 and TNF-ǂ have a role in major depressive 
disorder (Licinio and Wong, 1999). The involvement of proinflammatory cytokines in 
experimental animals shows that the alteration in biological and behavioural abnormalities, 
as an analogue found in depressive patients (Konsman et al., 2002). The behavioural change 
mediated by cytokine seems to be regulated by multiple pathways. IL-1 is mainly involved in 
anxiety and sickness behaviour (Montkowski et al., 1997; Tomonaga, 2004). Likewise, in BDV 
infected patients, there was an increase of IL-6 was observed (personal communication). 
Experiments with animal model infected with BDV clearly show that there is an increase in the 
cytokines IL-1ǂ, IL-6 and TNF-ǂ (Sauder and de la Torre, 1999; Shankar et al., 1992). This may 
be one of the pathways of BDV in inducing psychiatric behavioural and cognitive deficits. 
3.5.2 Role of serotonin system 
Virus infection can directly or indirectly alter the serotonin system. Proinflammatory 
cytokines can also alter the expression of serotonin system (Dunn, 2000). Alteration of 5-HT 
(hydroxyl-tryptophan) systems leads to several mental and behavioural problems that 
include aggression, violence, sexual dysfunction, sleep and eating disorder in humans 
(Manji et al., 2001) and in rat models, reduction of 5-HT increases aggression (Nelson and 
Chiavegatto, 2001). In transgenic mice expressing P protein, the serotonin receptors in the 
hippocampus are reduced as well as these mice exhibit neurobehavioral abnormalities as in 
BDV infected animals (Kamitani et al., 2003). The transgenic mice also exhibit insulin-like 
growth factor 3 in their astrocytes, suggesting the increased vulnerability of purkinje cells in 
the brain (Honda et al., 2011). 
3.6 Role of amantadine in BDV-infected psychiatric illness 
Amantadine has been reported as an effective drug in reducing BDV replication in vitro and 
in vivo (Bode et al., 1997; Dietrich et al., 2000; Ferszt et al., 1999). Amantadine sulphate was 
used as an antiviral therapy in patients with bipolar disorder and found to be remarkable 
(Bode et al., 1997). All human BDV isolates are sensitive to amantadine treatment in vitro 
(Bode and Ludwig, 2003). Since the molecular mechanism of amantadine is unknown, here 
we discuss a putative mechanism based on the current understanding.  
3.6.1 Amantadine in BDV infection 
Astrocytes play an essential role in the homeostasis of CNS microenvironment for the 
proper neuronal function, where the alteration of astrocytic function leads to neuronal 
pathology (Benveniste, 1992, 1997). The function of astrocytes in BDV infection has been 
intensively studied in various aspects; the ability to uptake glucose, protein synthesis, cell 
viability and rate of proliferation (Billaud et al., 2000), accumulation of macrophage 
migratory inhibitory factor in astrocytes (Bacher et al., 2002), the expression of tissue factor, 
a primary cellular initiation of the coagulation protein cascades, resulting in protease 
thrombin by astrocytes (Gonzalez-Dunia et al., 1996), astrocytes as an antigen-presenting 
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and target cells for virus specific CD4 lymphocytes (Richt and Stitz, 1992) and cytokine 
expression as a result of BDV infection resulting in neuropathology (Sauder and de la Torre, 
1999; Shankar et al., 1992). 
BDV infection has been reported in psychiatric illness by the presence of BDV RNA, antigen, 
circulating immune complex (CIC) in blood and post-mortem brain in psychiatric patients 
(Bode et al., 1997; Bode et al., 1995; Miranda et al., 2006; Sauder et al., 1996; Terayama et al., 
2003). Amantadine is said to improve psychiatric illness such as mania and depression in 
bipolar disease and depressive patients (Dietrich et al., 2000; Moryl et al., 1993; Ohlmeier et 
al., 2007; Ohlmeier et al., 2008). Further amantadine was shown to have no role against BDV 
infection (Cubitt and de la Torre, 1997; Hallensleben et al., 1997; Stitz et al., 1998). 
Amantadine inhibits replication of BDV in cells and also prevents the infection of the naïve 
cells (Bode et al., 1997; Bode et al., 2001). Amantadine may not be an antiviral agent that 
improves psychiatric illness in BDV infected patients. Here we hypothesize the role of 
amantadine in improvement of psychiatric illness in patients infected with BDV. 
3.6.1.1 Amantadine as a kinase inhibitor 
In BDV infection, Raf/MEK/ERK signalling cascade is activated due to the infection (Planz 
et al., 2001) and also BDNF induced ERK1/2 phosphorylation is blocked (Hans et al., 2004). 
Thus BDV involves in signalling cascade that results in abnormal signalling or reduction of 
synaptogenesis. The MEK-specific inhibitor U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-
aminophenylthio] butadiene) blocks the spread of BDV to the neighbouring cells, thereby 
infectious viral particle are concentrated in the nucleus. In the absence of the MEK-inhibitor, 
BDV regains the ability to spread in the cell culture and BDV infectious particles have been 
recovered from the infected cells, after the removal of MEK inhibitor. This showed that MEK 
inhibitor results in alteration of cellular or viral mediated process, subsequently the 
spreading from cell to cell, but does not interfere with the infectivity once the virus is 
released by cell disruption (Planz et al., 2001). Similarly amantadine was shown to prevent 
spreading to the naïve cells (Bode et al., 1997; Bode et al., 2001).  
In influenza virus infected human bronchial epithelial cells, amantadine exhibits inhibitory 
effect on p38 mitogen activated protein (MAP) kinase and c-Jun-NH2-terminal kinase (JNK) 
activity (Asai et al., 2001). Likewise, amantadine may act as a kinase inhibitor to relieve from 
mania or depression in BDV-infected psychiatric patients. Thus amantadine might acts as a 
kinase inhibitor allowing cellular changes in astrocytes. 
3.6.1.2 Amantadine and IL 6 
Astrocytes are one of the primary resident cells of the central nervous system with the 
production of cytokines. BDV-infections, neurons die both from direct viral lysis and 
immunopathological responses, while BDV-infected astrocytes appear to increase (Carbone 
et al., 1991a; Carbone et al., 1991b; Carbone et al., 1989). In rats, after intranasal infection 
with BDV, the proinflammatory cytokines mRNA namely interleukin (IL)-6, IL-1ǂ and TNF- 
ǂ were found to increase (Shankar et al., 1992). Similar results have been observed by 
Sauder and de la Torre (Sauder and de la Torre, 1999), in rats infected with BDV, the 
proinflammatory cytokines like IL-6, TNF-ǂ, IL-1ǂ, IL-1ǃ found to be increased in the 
hippocampus and cerebellum in the infected rats that shows distinct behavioural and 
neurodevelopmental abnormalities. It is obvious that infection results in the expression of 
cytokines by the astrocytes. 
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IL-6 expression can be induced by the proinflammatory cytokines, IL-1ǃ and TNF-ǂ via 
protein kinase C (PKC) in astrocytes (Di Santo et al., 1996; Norris et al., 1994). IL-6 can also 
be a destructive agent during dysregulation in CNS, where over-expression leads to 
neuropathological conditions that include neurodegeneration, breakdown of blood-brain 
barrier, angiogenesis and increased expression of complement proteins (Campbell et al., 
1993). The proinflammatory cytokines such as IL-6, TNF-ǂ, IL-1ǂ, IL-1ǃ is known to 
contribute in neuropsychiatric syndromes, especially in major depression (Licinio and 
Wong, 1999; Tomonaga, 2004). 
In BDV-infected psychiatric patients with bipolar mania or depression, after treatment with 
amantadine, there is a reduction in IL-6 and in BDV-CIC (personal communication). So the 
reduction in proinflammatory cytokine IL-6 shows that amantadine has some effects in 
treating BDV-infected patients. It suggests that treatment with amantadine regulates 
reduction of IL-6 and CIC in BDV infected patients. 
In conclusion, amantadine may reduce the spread of BDV by acting as a kinase inhibitor and 
thereby reduce the severity by inhibiting the spreading of BDV to the neighbouring cells and 
also results in reduction of IL-6 by alteration of cellular mechanism in signalling pathways. 
Thus, amantadine can be used clinically in treating BDV-infected psychiatric patients.  
3.7 Blood transfusion and BDV 
Blood transfusion and BDV is least studied, because of the lack of evidence for transmission 
in humans and; also as a causative agent for neuropsychiatric illness in humans. In few 
studies, BDV has been suggested as a contributing source for neuropsychiatric illness (Chen 
et al., 1999), but BDV and or its viral component has been reported to present in blood of 
psychiatric patients (Bode et al., 1997; Bode et al., 1996; Heinrich and Adamaszek, 2010; 
Kitani et al., 1996; Sauder et al., 1996). In animal models, the transfusion/transfer of 
lymphocytes from brain of BDV-infected to immuno-compromised rats results in clinical 
symptoms and neuropathology of Borna disease in the recipients (Batra et al., 2003). Thus, 
the need for blood test for BDV has been suggested to be included during blood donation 
and transfusion (Alwin Prem Anand, 2010). If the viral component and/or the lymphocyte 
are sufficient to cause the clinical symptoms and neuropathology in recipients, blood 
transfusion might result in the same. Though, it is really a question whether BDV is the 
causative agent of neuropsychiatric illness in human. But preferably BDV infection in 
human beings might worsen the symptoms of any neuropsychiatric illness, if present.  
4. Dengue viral disease 
Dengue is the most important arthropod-borne viral infection of humans, which affects 
millions of people, particularly in urban and semi-urban areas. Worldwide, an estimated 2.5 
billion people are at risk of infection (Gubler, 2002), with more than 100 million new 
infections each year. This includes 500,000 hospitalizations cases for dengue hemorrhagic 
fever, predominantly among children (Dussart et al., 2006). The annual average number of 
dengue fever/dengue hemorrhagic fever (DF/DHF) cases reported to the WHO has 
increased significantly in recent years. For the period 2000–2004, the annual average was 
925,896 cases; almost double the figure of 479,848 cases that was reported in the period 
1990–1999. Travelers’ from endemic areas serve as vehicles for further spread. Dengue 
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epidemics can have a significant economic and health toll. In endemic countries in Asia and 
the Americas, the burden of dengue is approximately 1,300 disability-adjusted life years per 
million populations, which is similar to the disease burden of other childhood and tropical 
diseases including tuberculosis in these regions (Gubler and Meltzer, 1999). 
4.1 Dengue virus genome structure and function 
Dengue viruses (DENV) belong to the genus flavivirus within the Flaviviridae family. The 
virus evolved in non-human primates from a common ancestor and entered the urban cycle 
some 500–1,000 years ago. The virus has a positive strand RNA whose genome is 
approximately 11kb in length. It has four antigenically distinct serotypes (Dengue virus 1-4). 
The RNA has a single open reading frame that encoding three structural proteins, 
nucleocapsid/core protein (C), membrane protein (M) and envelope protein (E) and; seven 
non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) (Chambers et al., 
1990). The envelope (E) and membrane proteins (M) are inserted in the lipid membrane. The 
glycoprotein E contains most of the antigenic determinants of the virus and essential for 
viral attachment and entry, while membrane protein (M) is synthesized as the precursor 
protein (prM), which acts as a chaperone during maturation of the viral particle. The 
nucleocapsid consists of capsid protein (C). 
4.2 Dengue infection 
Though dengue infection occurs as a mild febrile, self limiting illness i.e., Dengue fever (DF), 
its severe form causes Dengue hemorrhagic fever (DHF) and Dengue shock syndrome (DSS) 
are important public health problem because of its disease burden and high mortality rate 
(more than 5% in case of DHF/DSS) (Wilder-Smith et al., 2009). Infection by one serotype 
induces a lifelong immunity to the particular serotype and transient immunity to other 
serotypes, while concurrent infection by other serotype induces DHF/DSS. 
4.2.1 Stages of DENV infection 
In the skin, dengue viruses infect immature dendritic cells through the non-specific receptor 
dendritic cell specific ICAM3 grabbing non-integrin (DC-SIGN) (Wu et al., 2000). Infected 
dendritic cells mature and migrate to local or regional lymph nodes where they present viral 
antigens to T cells, initiating the cellular and humoral immune responses (Green et al., 1999). 
DENV also shown to replicate well in liver parenchymal cells, lymph node macrophages, 
liver, spleen, as well as in peripheral blood monocytes. DENVs produce several clinical 
syndromes, which depend up on age and immunological status of the individual. During 
initial stages, most infections are sub clinical (especially in children) or with mild 
undifferentiated febrile syndrome. In adults, primary infections with each of the four DENV 
serotypes, particularly with DENV-1 and -3, often results in DF. Some outbreaks of primary 
DENV-2 infections have been predominantly subclinical. During secondary dengue 
infections the pathophysiology of the disease changes dramatically. Sequential infections in 
which infection with DENV-1 is followed by infection with DENV-2 or DENV-3, or infection 
with DENV-3 is followed by infection with DENV-2 results in acute vascular permeability 
called as DSS (Alvarez et al., 2006). The severity of DSS is age-dependent and most severe in 
young children, which is due to the integrity of the capillaries (Gamble et al., 2000).  
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4.2.2 Genetic pre-disposition and host factors in DENV infection 
Dengue infections can be life-threatening when they occur in individuals with asthma, 
diabetes and other chronic diseases (Lee et al., 2006). Host factors that increase the risk of 
severe dengue disease include sex, several human leukocyte antigen class I alleles, promoter 
variant of the DC-SIGN receptor gene, single-nucleotide polymorphism in the tumour 
necrosis factor gene and AB blood group. Host factors that reduce the risk of severe disease 
during a second dengue infection includes race, malnutrition, and polymorphisms in the 
FcǄ receptor and vitamin D receptor genes (Martina et al., 2009).  
4.3 Pathogenesis of DENV infection 
In adults secondary dengue infections either produces the classical DSS or severe disease 
complicated by hemorrhages. Most notably, in island outbreaks the severity of secondary 
dengue infections has been observed to increase from month-to-month (Guzman et al., 
2000); and longer the interval between the first and second infection the more severe is the 
accompanying syndromes (Chareonsirisuthigul et al., 2007). 
4.3.1 Antibody Dependent Enhancement (ADE) 
Macrophages and monocytes participate in antibody dependent enhancement (ADE). 
Immune complexes formed between DENV antigens and non-neutralizing antibodies due to 
previous heterotypic dengue infections or from low concentrations of dengue antibodies of 
maternal origin in infant sera cross-react with Fc receptors of mononuclear phagocytes. The 
co-circulation of four DENV serotypes in a given population might augment the ADE 
phenomenon (Martina et al., 2009). One working hypothesis of dengue pathogenesis that is 
consistent with the available evidence is that severe disease in infants with primary 
infections and in older individuals with secondary infections is the result of ADE of 
infection of mononuclear phagocytes. Infection by an antibody–virus complex suppresses 
innate immune responses, increasing intracellular infection and generating inflammatory 
cytokines and chemokines that, collectively, result in enhanced disease. 
4.3.2 Cytokines and soluble mediators 
The infection of human monocytes and mature dendritic cells results in suppression of the 
interferon system and increases virus replication. Type I interferon-associated genes are less 
activated severe dengue disease. Increased number of infected cells presenting targets for 
CD4+ and CD8+ T cells, results in large quantities of interleukin IL-10, IL-2, interferon 
(IFN)-Ǆ and TNF which lonely or synergistically, contributes to endothelial damage and 
altered homeostasis (Bosch et al., 2002; Talavera et al., 2004). Sub viral particles and virions 
released from infected cells also damages endothelial cells. Uptake of the non-structural 
protein NS1 by hepatocytes promotes viral infection of the liver. During DHF, the 
complement cascade is also activated and the levels of the complement activation products 
C3a and C5a correlate with the severity of illness (Malasit, 1987). Soluble and membrane-
associated NS1 have been demonstrated to activate human complement. The levels of 
plasma NS1 correlated with disease severity, suggesting links between the virus, 
complement activation and the development of DHF/DSS (Navarro-Sanchez et al., 2005). 
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Alternative hypothesis for dengue pathogenesis points out the role of secondary T-cell 
responses. Researches point that the stimulation of T-cell memory results in the production 
of heterotypic CD4 and CD8 cells, which are less powerful in killing but release considerable 
amount of pro-inflammatory cytokines that contribute to disease severity. Cross-reactivity 
between antibodies produced against NS with human platelets, and endothelial cells, 
damages these cells. In patients with DF, IFN production and activated natural killer cells 
can limit disease severity (Mongkolsapaya et al., 2003; Zivna et al., 2002). 
4.4 DENV transmission by non-vector modes 
Other mosquito-borne flavivirus, such as West Nile virus, is transmitted efficiently in breast 
milk, blood transfusion, organ transplantation, stem cell transplantation, intra-uterine 
exposure and needle stick injuries (Hong et al., 2003; Iwamoto et al., 2003). The main 
transmission route for DENV is by vector mosquito. It is also transmitted by needle stick 
injuries, bone marrow transplantation and intrapartum vertical transmissions (Rodriguez 
Rodriguez et al., 2009). Recent reports have demonstrated dengue viremia in blood donors 
from Honduras, Brazil, Australia and Puerto Rico, which are endemic areas for dengue 
infection. Transmission of dengue infection has been reported from donor to recipient in one 
case of living donor renal transplant (Tan et al., 2005). The clinical presentation and course 
of illness was similar to that of an immuno-competent patient, except for prolonged course 
of illness (19 days) and duration of thrombocytopenia. Transmission during a bone marrow 
transplant was reported in one instance during a dengue epidemic in Puerto Rico in 1994 
(Rigau-Perez et al., 2001).  
4.4.1 Individual reported cases of transfusion mediated transmission 
There are only two reported instances of transmission through blood transfusion. The first 
involved a patient in Hong Kong who developed fever 3 days after a blood transfusion, 
associated with moderate neutropenia, severe thrombocytopenia and hypotension 
responsive to fluid therapy. The donor was asymptomatic at the time of donation but 
developed mild symptoms of DF 1 day after blood donation. Stored sample from the donor 
tested positive for dengue virus by RT-PCR (Chuang et al., 2008). The second involved the 
transmission of dengue from an asymptomatic blood donor from Singapore who developed 
an acute febrile illness the day after donating blood. Investigation confirmed dengue 
infection in the recipients of the three blood products from his donation. Two recipients had 
DF with some evidence of capillary leakage, whereas the platelet recipient had 
asymptomatic seroconversion and all patients recovered. A stored serum sample from the 
donation tested positive for DEN-2 by RT-PCR (Tambyah et al., 2008).  
4.4.2 Population based study on DENV transmission through transfusion 
Various studies have shown the presence of asymptomatic or subclinical infection, which 
can range from 0.77 to 87% depending on the population studied (Ooi et al., 2006). It is 
estimated that for every one symptomatic case, there can be 6.7 cases that are asymptomatic 
(Chen and Wilson, 2005). A study found silent transmission of dengue commonly in 15 to 40 
year age group. Among 329 healthy volunteers in a province in Thailand with high rate of 
dengue infection, 29 (8.8%) had a serum sample positive for dengue IgM, of which two 
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samples tested positive for viral RNA (Poblap et al., 2006). Cluster sampling studies around 
index cases in Indonesia detected eight asymptomatic dengue infections of 785 volunteers 
over a 2-year period, of which two demonstrated viraemia by RT-PCR (Beckett et al., 2005). 
Virus was isolated in 215 of 3189 (6.7%) persons in a study evaluating the dynamics of 
transmission of dengue virus in a dengue epidemic area of Colombia, most of who were 
asymptomatic (Mendez et al., 2006). Two recent studies reported viraemia in blood 
donations collected from four countries experiencing high dengue transmission rates. In the 
first study, twelve (0.07%) of 16,521 blood donations collected in Puerto Rico tested positive 
using the dengue-specific nucleic acid amplification test (NAT). Testing using RT-PCR was 
positive in four samples and live virus was recovered from three of the PCR-positive 
samples (Mohammed et al., 2008). In the second study, samples from asymptomatic blood 
donors in Honduras, Brazil and Australia were obtained during periods of clinical dengue 
outbreaks and screened using the dengue-specific TMA assay. Nine (0.30%) of 2994 
Honduran samples were tested positive, of which 8 were confirmed by RT-PCR and 4 
samples yielded infectious viruses. Three (0.06%) of 4858 Brazilian samples tested positive, 
of which 2 were RTPCR positive (Linnen et al., 2008). 
Technically, it is possible for DENV to be transmitted through blood transfusions because 
the disease courses with a transient viremia after infection and can be asymptomatic or have 
only mild symptoms. DENV was identified as one of three high-priority infectious agents 
with actual or potential risk of transfusion transmission in the United States or Canada. The 
rate of asymptomatic DENV infection in blood donors has been determined retrospectively 
in Puerto Rico and several other countries where dengue is endemic using molecular 
diagnostic. Infection rates have been shown to vary with disease incidence in the 
community, including the seasonal variation of dengue. In Puerto Rico, nearly 1 in 1000 
blood donations were positive for DENV nucleic acid by during the 2005 dengue season 
(Mohammed et al., 2008) versus 1 in 600 positive during the 2007 outbreak (Tomashek and 
Margolis, 2011). The prevalence of DENV nucleic acid in blood donations in Puerto Rico in 
2005 was similar to that estimated for WNV in areas experiencing outbreaks in the United 
States in 2002 before universal screening was implemented in 2003. 
4.5 Challenges in identifying DENV as a risk in blood transfusion 
Lack of knowledge in endemic areas - researchers and clinicians may not know/ consider 
blood transfusion as a source of infection. 
Inconclusive data of dengue cases - may have been transfusion transmitted but has not 
been confirmed due to unavailability of complete information and serological tests.  
Presence of high rate of existing antibodies - among transfusion recipients and donors 
especially in endemic areas will hinder to calculate the actual risk of dengue after transfusion. 
4.6 Serological testing for DENV 
At present, the only approach to prevent transfusion of DENV-positive blood would be 
screening with sensitive nucleic acid amplification tests to detect asymptomatic DENV 
infections in otherwise healthy donors and asymptomatic viremia in the 24 to 48 hours 
before donors becoming ill with dengue. Exclusion of donors in endemic areas during the 
high-incidence dengue season or during an outbreak is not feasible since the entire 
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population is at risk of DENV infection, the need for blood components is typically high 
during outbreaks, and outbreaks can be long lasting.  
The small number of reports of transfusion transmission could be because of the fact that it 
is difficult to differentiate between non-mosquito transmission and mosquito mediated 
transmission.  Future studies are needed to establish rates of transfusion-transmitted DENV 
by viremic donations and their clinical consequences in recipients (Chen and Wilson, 2005). 
These evaluations should determine the most cost and prevention-effective approaches to 
prevent transfusion-transmitted dengue infections. 
5. Conclusion 
Hence, both BDV and DENV are less studied in transfusion medicine. It might be due to the 
incomplete evidence of transmission in BDV and, non-availability of better testing module 
for DV. In both the cases, the severity of causing serious damage to health is pretty high. The 
evidence for causing neuropsychiatric illness in BDV has not been proven or there is lack of 
evidence in it, but it may worsen the situation of a patient who is suffering from any prior 
neuropsychiatric illness. Ignoring the need for testing of the presence of these viruses in 
blood transfusion might result in serious health issues at global level. So in order to prevent 
potential risk of BDV and DENV infection through transfusion medicine, precautionary 
measures should be taken to diagnose and prevent BDV and DENV infection during blood 
transfusion. 
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